SecBot SecBot
Biotech Drug Report Generated Sep 13, 2026

LP-284

LTRN·Lantern Pharma Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Unknown, still in Phase 1 dose-escalation. If Phase 1 completes successfully, Phase 2/3 would follow, meaning at least 3-5 years to potential approval, if ever.
Why 4/10
LP-284 is a Phase 1 asset with no scheduled PDUFA date or pivotal readout in the next ~12 months. The next catalyst would be additional Phase 1 data at a medical conference, but no specific date is confirmed. Lantern has a multi-asset pipeline (LP-184, LP-300 also in trials), so LP-284 is not the sole value driver. Per the rubric, a mid-stage drug with no dated binary catalyst within 12 months scores 3-5; 4 reflects the early efficacy signal (complete response in DLBCL) balanced against Phase 1 risk and lack of a hard catalyst date.
Actionable Insight NEUTRAL

Watch for the next Phase 1 data update from LP-284's ongoing trial (NCT06132503), likely at a hematology/oncology medical conference in H1 2027. The stock is highly speculative at ~$1.71 with a ~923% implied analyst upside, but Phase 1 assets carry high failure risk. Monitor cash runway, Lantern's May 2026 offering raised capital but also diluted existing holders. Any meaningful partnership or accelerated development pathway would be a major positive catalyst.

Price Chart

Loading chart...

Executive Summary

LP-284 is a Phase 1 small-molecule drug from Lantern Pharma (LTRN, ~$1.71/share) that targets DNA repair deficiencies in cancer cells via a synthetic lethal mechanism. It belongs to the acylfulvene family and is a stereoisomer of the company's other asset, LP-184. LP-284 has shown early promise: a complete metabolic response in a heavily pre-treated DLBCL patient who had failed CAR-T and bispecific antibody therapy, presented at the October 2025 LL&M Congress. The drug has three FDA Orphan Drug Designations (mantle cell lymphoma, high-grade B-cell lymphoma, and soft tissue sarcomas). However, it remains in early-stage Phase 1 testing with no pivotal readout or PDUFA date on the horizon. Lantern Pharma is a micro-cap (market cap likely ~$22M based on ~12.8M shares at $1.71) with a pipeline of three clinical-stage assets, so LP-284 is a meaningful but not sole value driver. Analyst targets average $17.50, implying massive upside, but the stock trades near its 52-week low of $1.11, reflecting the risk of early-stage development and likely cash runway/dilution concerns.

How It Works

LP-284 is a small molecule that exploits a vulnerability in certain cancer cells' DNA repair systems. It belongs to a class called acylfulvenes and works through a "synthetic lethal" mechanism, it targets cancer cells that have defective DNA repair pathways (specifically the transcription-coupled nucleotide excision repair or TC-NER pathway), causing them to accumulate lethal DNA damage while sparing healthy cells. This mechanism works regardless of TP53 mutation status, which is relevant because TP53 is commonly mutated in many cancers.

Trial Status

LP-284 is in an ongoing Phase 1 dose-escalation trial (NCT06132503) enrolling adult patients with relapsed/refractory B-cell Non-Hodgkin's Lymphomas and solid tumors. Early data presented at the October 2025 LL&M Congress showed a complete metabolic response in a heavily pre-treated DLBCL patient who had failed both CAR-T and bispecific antibody therapies. The trial is actively recruiting.

The Two-Sided Case

▲ Bull Case5
Early efficacy signal is compelling: a complete metabolic response in a DLBCL patient who had exhausted CAR-T and bispecific antibody therapies, a very difficult-to-treat population (source: Lantern Pharma press release, Oct 2025 LL&M Congress)
Three FDA Orphan Drug Designations (mantle cell lymphoma, high-grade B-cell lymphoma, soft tissue sarcomas) provide market exclusivity potential and development incentives (source: FDA catalysts data, SEC filings)
Analyst consensus is strongly bullish: 7 of 8 analysts rate Buy/Strong Buy with a mean price target of $17.50, implying ~923% upside from $1.71
Institutional accumulation: Renaissance Technologies doubled its position (+150.9%), Vanguard added (+28%), and UBS added (+65%) in Q2 2026
Two directors each purchased $100K of stock at $2.06/share in May 2026, signaling insider confidence
▼ Bear Case5
Phase 1 only, the vast majority of Phase 1 oncology drugs never achieve FDA approval; early single-patient complete responses often fail to replicate in larger cohorts
Micro-cap risk: LTRN trades near $1.71 with a ~$22M market cap; the May 2026 securities offering that raised capital also diluted existing shareholders (insider warrants at $2.27 strike)
Mixed institutional signals: BlackRock trimmed -50.6% and Dimensional Fund Advisors trimmed -56.1% of their LTRN positions in Q2 2026
Short interest of 4.42% of estimated shares outstanding with 4.16 days to cover suggests some bearish positioning (source: FINRA short positions data, Aug 31, 2026)
No near-term binary catalyst, no PDUFA date, no Phase 2/3 readout scheduled; the stock lacks a hard event to drive re-rating in the next 12 months

Upcoming Catalysts

  • Next Phase 1 clinical data update (likely at a hematology/oncology conference in 2027)
  • Potential additional Orphan Drug Designations or Fast Track designations
  • Possible partnership/licensing deal given early efficacy signal in DLBCL

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Lantern Pharma Inc. 8-K LTRN ·Originating report

Sources · 9

Hover a chip for the title
1 ir.lanternpharma.com2 ir.lanternpharma.com3 ir.lanternpharma.com4 lanternpharma.com5 lanternpharma.com6 clinicaltrials.gov7 curetoday.com8 biospace.com9 biospace.com